LGALS1 and obesity disorder: Thus, hPL inhibitors can reduce the hydrolysis of dietary lipids in the gastrointestinal tract by decreasing the hydrolytic activity of hPL, thereby alleviating the symptoms of obesity and overweight [11,12,13].